Especially blocking of the cytotoxic T lymphocyte-associated protein-4 (CTLA-4), the programmed death (PD)-1 T cell receptor, and its ligand PD-L1 have shown to be promising targets to activate the immune system to attack cancer cells. The gene discussed is CTLA4; the disease is cancer.